Furthermore, a recent study investigating the effects of an NLRP3 inhibitor, OLT1177® (dapansutrile), demonstrated that—in an experimental mouse model of AMI due to myocardial ischemia-reperfusion injury—OLT1177® (6, 60, or 600 mg/kg i.p.), when administered within 60 min following ischemia-reperfusion injury, significantly inhibited the caspase-1 activity in the heart, preserved the cardiac contractile function, and reduced the size of the infarct. The gene discussed is NLRP3; the disease is ischemia reperfusion injury.